StockData

PureTech Health plc (PTCHF) company profile

PTCHFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as PRTCY
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 2/30
$1.48+0.00 (0.00%)

Close on Oct 19, 2026Market cap –P/E –Yield –

About PureTech Health

Pharmaceutical Preparations, SIC 2834

PureTech Health operates as a biotherapeutics entity focused on developing treatments across several dedicated operational segments, primarily targeting oncology and related clinical areas through subsidiary operating units. The company conducts its research and development programs both directly and through subsidiary operating companies such as Gallop Oncology, Entrega, PureTech LYT, and PureTech LYT 100. These programs are designed to advance targeted biotherapeutic candidates for patients, while also managing historical interests in deconsolidated former subsidiaries and inactive corporate entities.

The group maintains its operating activities across distinct organizational units including Wholly-Owned segments, Controlled Founded Entities, and Parent Company and Other operations. PureTech conducts business activities supported by technical facilities featuring specialized laboratory and manufacturing equipment, computer infrastructure, and fixtures. Corporate operations and segment administrative activities are coordinated across these designated operating divisions and corporate holding structures.

Summary of the business section of PureTech Health's latest annual report, written by StockData.

Company profile

Company

Legal name
PureTech Health plc
Headquarters
Boston, MA
Address
6 Tide Street, Suite 400 02210
Phone
(617) 482-2333
Industry
Pharmaceutical Preparations
Incorporated in
X0
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
PTCHF
Other tickers
PRTCY
Former tickers
PRTC until Apr 29, 2026
Exchange
OTC
IPO date
Jul 29, 2015
Shares outstanding
242M, Dec 31, 2025
Filer category
Accelerated filer
SEC CIK
1782999
CUSIP
746237106
ISIN
US7462371060
FIGI
BBG009PZZ6P6
Share class FIGI
BBG0099R11Y0
LEI
213800LVPDNO2Z9T9I39
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

PureTech Health's leadership is listed in its proxy statement (Form DEF 14A).

Corporate history

Events identified from SEC filings

DateEventDetails
May 21, 2026DeregistrationTermination of SEC registration (Form 15)
May 11, 2026DelistingNotice of delisting from exchange (Form 25)

See a number that looks wrong?